Abstract

This study focused to study the efficacy and safety of magnesium sulfate with nifedipine for pregnancy-induced hypertension receiving evidence-based care. 100 pregnancy-induced hypertension individuals who were treated between January 2022 and December 2022 were selected. On the basis of evidence-based care, 54 patients were given magnesium sulfate with nifedipine and were assigned as research group while 46 individuals were treated with magnesium sulfate alone and were regarded as control group. Data on clinical efficacy, systolic and diastolic blood pressure, heart rate and other complications rate like dyspnea, accelerated heart rate, and nausea and vomiting were comparatively analyzed. Similarly, information regarding umbilical artery resistance index, blood viscosity and adverse pregnancy outcomes such as postpartum hemorrhage, placental abruption and cesarean section were collected among the patients for comparison. The data showed an obviously higher overall response rate of treatment in the research group compared with the control group. Besides, the research group exhibited markedly reduced systolic and diastolic blood pressure, heart rate, umbilical artery resistance index and blood viscosity after treatment were low compared with the control group. Moreover, statistically lower incidence rates of complications and adverse pregnancy outcomes were determined in the research group. The above shows that magnesium sulfate with nifedipine has a beneficial effect on improving the curative effect of pregnancy-induced hypertension patients receiving evidence-based care while ensuring the treatment safety, contributing to better blood pressure and heart rate control, inhibited umbilical artery resistance index and blood viscosity, and a reduced risk of adverse pregnancy outcomes, which is worth of clinical promotion.